Trius Therapeutics, Inc. (TSRX)

[kris_kade]

Trius is sum of all these parts and more

1. $1 billon market
2. Zyvox includng its generic version killer
3. Great gram-negative pipeline
4. Recent discovery of new class of antibiotics granted few years away from commercialization
5. Partnership for Euro markets
6. Lastly buyout

With approval close to being certain, there are very few less risker biotechs out there that have this low valuation.